Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy
International Immunology · 2025
DOI: 10.1093/intimm/dxaf003 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2025. Verfasst von Ehab M Ezzaldeen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto…. Hauptthemen laut MEDLINE: Photochemotherapy, Immunotherapy, Porphyrins, Photosensitizing Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meiji Holdings Co., Ltd and Meiji Seika Pharma Co., Ltd, and JST SPRING.
Abstract (Originalsprache)
Photodynamic therapy (PDT), a local cancer treatment using photosensitizers, has been reported to enhance antitumor immune responses by inducing immunogenic cell death. Although several studies have demonstrated the synergistic antitumor effects of PDT and immune checkpoint blockage (ICB), the detailed underlying mechanisms remain poorly understood. In this study, we investigated the immunological effects of PDT with talaporfin (Tal-PDT), a clinically approved photosensitizer, using bilateral tumor-bearing mouse models. Treatment with Tal-PDT on the tumor on one side of the mouse resulted in tumor growth inhibition on the untreated opposite side. This phenomenon, accompanied by tumor antigen-specific immune reactions, is indicative of an abscopal effect. When combined with anti PD-L1 antibody, synergistic antitumor effects were observed on both the laser-treated and untreated sides. Mechanistically, Tal-PDT enhanced the induction of XCR-1+ dendritic cells in the proximal draining lymph node likely through the induction of ferroptosis in tumor cells. This, in turn, led to the systemic generation of precursor-exhausted CD8+ T cells. Moreover, talaporfin was selectively incorporated into tumor cells rather than into tumor-infiltrating T cells in vivo, leading to targeted tumor killing while preserving T cells. These beneficial effects of Tal-PDT on antitumor immunity collectively enhance ICB cancer immunotherapy. Our study demonstrates the potential of combining Tal-PDT with ICB therapy for clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Immuno-Oncology PDT, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Pharmacokinetics and Toxicology Group, Drug Discovery Department, R&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan.
- Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Tomonori Yaguchi, Kosaku Murakami, Manabu Muto
Förderung
- Meiji Holdings Co., Ltd and Meiji Seika Pharma Co., Ltd, and JST SPRING
Zitieren
APA
Ezzaldeen, E. M., Yaguchi, T., Imagawa, R., Soltan, M. A., Hirata, A., Murakami, K., Tsukamoto, H., Muto, M., Honjo, T., & Chamoto, K. (2025). Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy. International Immunology. https://doi.org/10.1093/intimm/dxaf003
Vancouver
Ezzaldeen EM, Yaguchi T, Imagawa R, Soltan MA, Hirata A, Murakami K, et al. Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy. International Immunology. 2025. doi:10.1093/intimm/dxaf003
BibTeX
@article{Ezzaldeen2025,
author = {Ezzaldeen, Ehab M and Yaguchi, Tomonori and Imagawa, Ryotaro and Soltan, Mohamed A and Hirata, Akira and Murakami, Kosaku and Tsukamoto, Hirotake and Muto, Manabu and Honjo, Tasuku and Chamoto, Kenji},
title = {Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy},
journal = {International Immunology},
year = {2025},
doi = {10.1093/intimm/dxaf003}
}
EUVIMED